ReviewBiochimica et biophysica acta2008
Lysophospholipid interactions with protein targets.
Review in Biochimica et biophysica acta, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Atomistic modeling of lysophospholipids from the Campylobacter jejuni lipidome.Biophysical journal · 2025Article
- Entering, Linked with the Sphinx: Lysophosphatidic Acids Everywhere, All at Once, in the Oral System and Cancer.International journal of molecular sciences · 2023Review
- Structural evidence of the species-dependent albumin binding of the modified cyclic phosphatidic acid with cytotoxic properties.Bioscience reports · 2016Article
- Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal.PLoS biology · 2014Article
- Unlocking the biology of RAGE in diabetic microvascular complications.Trends in endocrinology and metabolism: TEM · 2014Review
- Lipid phosphate phosphatase (LPP3) and vascular development.Biochimica et biophysica acta · 2013Review
- Ligand-based autotaxin pharmacophore models reflect structure-based docking results.Journal of molecular graphics & modelling · 2011Article
- Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.ChemMedChem · 2011Article
- Endocannabinoids and diacylglycerol kinase activity.Biochimica et biophysica acta · 2011Article
- Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.Bioorganic & medicinal chemistry letters · 2010Article
- 2D binary QSAR modeling of LPA3 receptor antagonism.Journal of molecular graphics & modelling · 2010Article
- Synthesis of lysophospholipids.Molecules (Basel, Switzerland) · 2010Review
- Improved method for the quantification of lysophospholipids including enol ether species by liquid chromatography-tandem mass spectrometry.Journal of lipid research · 2010Article
- Structure-based drug design identifies novel LPA3 antagonists.Bioorganic & medicinal chemistry · 2009Article
- Lysophosphatidic Acid signals through specific lysophosphatidic Acid receptor subtypes to control key regenerative responses of human gingival and periodontal ligament fibroblasts.Journal of periodontology · 2009Article
- Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.The Journal of biological chemistry · 2009Article
- Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect.The Journal of biological chemistry · 2009Article
- Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.Bioorganic & medicinal chemistry · 2009Article
- Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction.Journal of cardiovascular pharmacology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Bioactive lysophospholipids include lysophosphatidic acid (LPA), sphingosine 1-phosphate (S1P), cyclic-phosphatidic acid (CPA) and alkyl glycerolphosphate (AGP). These lipid mediators stimulate a variety of responses that include cell survival, proliferation, migration, invasion, wound healing, and angiogenesis. Responses to lysophospholipids depend upon interactions with biomolecular targets in the G protein-coupled receptor (GPCR) and nuclear receptor families, as well as enzymes. Our current understanding of lysophospholipid interactions with these targets is based on a combination of lysophospholipid analog structure activity relationship studies as well as more direct structural characterization techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and experimentally-validated molecular modeling. The direct structural characterization studies are the focus of this review, and provide the insight necessary to stimulate structure-based therapeutic lead discovery efforts in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.